274 related articles for article (PubMed ID: 19099668)
1. [Role of flow cytometric immunophenotyping in diagnosis of myelodysplastic syndromes--review].
Zhang Y; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1477-81. PubMed ID: 19099668
[TBL] [Abstract][Full Text] [Related]
2. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
3. [Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome].
Lu D; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):785-90. PubMed ID: 23815941
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
6. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
7. The role of flow cytometric immunophenotyping in myelodysplastic syndromes.
Pagnucco G; Giambanco C; Gervasi F
Ann N Y Acad Sci; 2006 Nov; 1089():383-94. PubMed ID: 17261782
[TBL] [Abstract][Full Text] [Related]
8. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
[TBL] [Abstract][Full Text] [Related]
9. [The role of bone marrow cells immunophenotypic study by flow cytometry in diagnosing myelodysplastic syndrome].
Czyz A; Dworacki G; Komarnicki M
Postepy Hig Med Dosw (Online); 2008 Jul; 62():354-63. PubMed ID: 18688206
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?
Cremers EM; Alhan C; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):14-21. PubMed ID: 25659726
[TBL] [Abstract][Full Text] [Related]
11. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.
Della Porta MG; Lanza F; Del Vecchio L;
Cytometry B Clin Cytom; 2011; 80(4):201-11. PubMed ID: 21674774
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
[TBL] [Abstract][Full Text] [Related]
15. [Advances of study on immunophenotyping of myelodysplastic syndromes-review].
Qiao C; Fan L; Wu YJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1106-10. PubMed ID: 19698271
[TBL] [Abstract][Full Text] [Related]
16. [Abnormality of immunophenotyping in patients with myelodysplastic syndrome].
Xu J; Guo YX; Zhao H; Hui WH; Wan SG; Sun XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):894-7. PubMed ID: 19698224
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes.
Xu F; Wu L; He Q; Zhang Z; Chang C; Li X
Intern Med J; 2012 Apr; 42(4):401-11. PubMed ID: 22032631
[TBL] [Abstract][Full Text] [Related]
19. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
20. Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?
Porwit A
Curr Hematol Malig Rep; 2015 Sep; 10(3):309-17. PubMed ID: 26122389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
